Xpert® C. difficile/Epi
45-minute detection & differentiation of Clostridium difficile & the Epidemic 027 strain
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
GXCDIFF/EPI-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
product image
Collection Device
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
product image
Single Use Disposable Swab (Pack of 120)
SDPS-120
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support

The Need

Numerous outbreaks caused by the epidemic strain of C. difficile (027/NAP1/BI strain) highlight the need for rapid and accurate differentiation of C. difficile 027/NAP1/BI strains in order to stay ahead of an outbreak.
  • Higher risk of cross contamination with 027/NAP1/BI strain due to more efficient sporulation1,2,3
  • 027/NAP1/BI strain has been identified as a cause of outbreaks around the world4,5,6,7,8
  • Incremental costs due to C. difficile infection can be as high as $7,1799 per patient
1. ÅkerlundT, et al. Increased Sporulation Rate of Epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol. Apr 2008, 46 (4) 1530-1533.
2. Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005 Sep 24-30;366(9491):1079-84.
3. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006 Nov 21;145(10):758-64.
4. Kallen AJ, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol. 2009 Mar;30(3):264-72.
5. Kuijper EJ, et al. Update of Clostridium difficile-associated Disease due to PCR Ribotype 027 in Europe. Eurosurveillance. Apr–Jun 2007. 12(3-6):163-166.
6. Muto CA, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis. 2007 Nov 15;45(10):1266-73.
7. McDonald LC, et al. An Epidemic, Toxin Gene-variant Strain of Clostridium difficile. N Engl J Med. 2005 Dec 8;353(23):2433-41.
8. Loo VG, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 Dec 8;353(23):2442
9. Jarvis WR, et al. National Point Prevalence of Clostridium difficile in US Health Care Facility Inpatients, 2008. Am J Infect Control. 2009 May;37(4):263-70.
10. Xpert® C. difficile/Epi Package Insert. 300-9680,Rev J. Apr 2020.

The Solution

Xpert C. difficile/Epi is the first commercially available test in the world to detect and differentiate the epidemic strain of C. difficile (027/NAP1/BI). With rapid and accurate identification of epidemic strain, Infection Control professional can stay ahead of potential outbreak situation.
  • Innovative multiplex design enables detection of C. difficile Infection (CDI) and 027/NAP1/BI strain call-out in a single cartridge
  • On-Demand testing of samples from suspected CDI patients provides On-Demand epidemiological surveillance data clinicians can act on
  • Monitoring and reporting of the epidemic strain enables clinicians to improve infection control efforts
Cepheid's Xpert C. difficile/Epi test provides on-demand results you can trust and empowers your clinical team to better manage patients.